Updated
The most significant concentration Zimmer Biomet Holdings discloses is single-source materials and components, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Zimmer Biomet Holdings’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'Certain of these materials and components and outsourced activities can only be obtained from a single source or a limited number of sources due to quality considerations'”
The company's disclosed concentration is a high-share supply dependency: certain materials and components and outsourced activities can only be obtained from a single source or a limited number of sources due to quality considerations — a large, high-share dependency by disclosed size. The character is dependency: the rationale given is quality — meaning these inputs require the precision, regulatory qualification, or proprietary specifications of a specific supplier — rather than a market structure that simply lacks alternatives. This makes the dependency relatively stable in calm conditions but potentially difficult to remediate quickly if a supplier fails, exits the market, or encounters a quality or regulatory issue, because qualifying a substitute for quality-driven sole-source inputs typically involves validation processes measured in months or years. For a medical device and orthopedic implant manufacturer, the consequence of a supply disruption is not merely a cost increase but a potential inability to produce specific products until the supply chain is restored or an alternative is qualified. That makes this a risk channel with disproportionate operational impact relative to its share of the input cost base. There are no disclosed customer, geographic, or product concentration risks at a comparable level, which limits compounding on the revenue side. The concentration profile is therefore anchored by a single supply-side risk. The relevant due-diligence questions are which specific product lines rely on sole-sourced materials, what inventory buffers or supplier qualification programs are in place, and whether the company has contingency sourcing arrangements for the most critical inputs.
For the engine’s reasoning on ZBH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| ZBH● | Zimmer Biomet Holdings, Inc. | 1 | 0 | 0 | 1 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.